A Study of SHR-4394 Injection in Subjects With Prostate Cancer

NCT06783829 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: SHR4394

Sponsor

Jiangsu HengRui Medicine Co., Ltd.